Computational Approaches to Drug Repurposing and Pharmacology

Data in the biological, chemical, and clinical domains are accumulating at ever-increasing rates and have the potential to accelerate and inform drug development in new ways. Challenges and opportunities now lie in developing analytic tools to transform these often complex and heterogeneous data into testable hypotheses and actionable insights. This is the aim of computational pharmacology, which uses in silico techniques to better understand and predict how drugs affect biological systems, which can in turn improve clinical use, avoid unwanted side effects, and guide selection and development of better treatments. One exciting application of computational pharmacology is drug repurposing- finding new uses for existing drugs. Already yielding many promising candidates, this strategy has the potential to improve the efficiency of the drug development process and reach patient populations with previously unmet needs such as those with rare diseases. While current techniques in computational pharmacology and drug repurposing often focus on just a single data modality such as gene expression or drug-target interactions, we rationalize that methods such as matrix factorization that can integrate data within and across diverse data types have the potential to improve predictive performance and provide a fuller picture of a drug's pharmacological action.

[1]  M. Mezei,et al.  Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.

[2]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[3]  E. Schadt,et al.  Integrative genomics and drug development. , 2009, Pharmacogenomics.

[4]  Hao Ding,et al.  Similarity-based machine learning methods for predicting drug-target interactions: a brief review , 2014, Briefings Bioinform..

[5]  K I Kaitin,et al.  Deconstructing the Drug Development Process: The New Face of Innovation , 2010, Clinical pharmacology and therapeutics.

[6]  Evan Bolton,et al.  PubChem's BioAssay Database , 2011, Nucleic Acids Res..

[7]  Ruili Huang,et al.  Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays , 2015, PloS one.

[8]  Gary K. Chen,et al.  Genotype imputation via matrix completion , 2013, Genome research.

[9]  E. Gabrilovich,et al.  Postmarket Drug Surveillance Without Trial Costs: Discovery of Adverse Drug Reactions Through Large-Scale Analysis of Web Search Queries , 2013, Journal of medical Internet research.

[10]  Ying Li,et al.  Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality , 2014, J. Am. Medical Informatics Assoc..

[11]  Xiang-Sun Zhang,et al.  Two-stage flux balance analysis of metabolic networks for drug target identification , 2011, BMC Systems Biology.

[12]  Gerald M. Maggiora,et al.  On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..

[13]  Olivier Bodenreider,et al.  The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..

[14]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[15]  Yan Zhao,et al.  Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.

[16]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[17]  Steven Simoens,et al.  A comparative study of European rare disease and orphan drug markets. , 2010, Health policy.

[18]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[19]  Ahmed Enayetallah,et al.  Causal reasoning on biological networks: interpreting transcriptional changes , 2012, Bioinform..

[20]  M. Ghert,et al.  Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.

[21]  Jean-Philippe Vert,et al.  Protein-ligand interaction prediction: an improved chemogenomics approach , 2008, Bioinform..

[22]  Thomas Hartung,et al.  Food for thought... on the economics of animal testing. , 2009, ALTEX.

[23]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[24]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[25]  Mathias Jucker,et al.  The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.

[26]  G. Andriole,et al.  The effect of finasteride in men with benign prostatic hyperplasia. , 1992, The Journal of urology.

[27]  S. Lee,et al.  Metabolic network modeling and simulation for drug targeting and discovery , 2012, Biotechnology journal.

[28]  S. Horvath,et al.  Statistical Applications in Genetics and Molecular Biology , 2011 .

[29]  Andrew D. Rouillard,et al.  LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures , 2014, Nucleic Acids Res..

[30]  James G. Nourse,et al.  Reoptimization of MDL Keys for Use in Drug Discovery , 2002, J. Chem. Inf. Comput. Sci..

[31]  Jason A. Papin,et al.  Mechanistic systems modeling to guide drug discovery and development. , 2013, Drug discovery today.

[32]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[33]  Kumanan Wilson,et al.  Effectiveness of smoking cessation therapies: a systematic review and meta-analysis , 2006, BMC public health.

[34]  Albert-László Barabási,et al.  Scale-Free Networks: A Decade and Beyond , 2009, Science.

[35]  Dennis M. Krüger,et al.  Comparison of Structure‐ and Ligand‐Based Virtual Screening Protocols Considering Hit List Complementarity and Enrichment Factors , 2010, ChemMedChem.

[36]  Sheng-Yong Yang,et al.  Pharmacophore modeling and applications in drug discovery: challenges and recent advances. , 2010, Drug discovery today.

[37]  Jeffrey Skolnick,et al.  A Comprehensive Survey of Small-Molecule Binding Pockets in Proteins , 2013, PLoS Comput. Biol..

[38]  Noel M. O'Boyle Towards a Universal SMILES representation - A standard method to generate canonical SMILES based on the InChI , 2012, Journal of Cheminformatics.

[39]  Yanli Wang,et al.  PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .

[40]  Jianxin Chen,et al.  Matrix Factorization-Based Prediction of Novel Drug Indications by Integrating Genomic Space , 2015, Comput. Math. Methods Medicine.

[41]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[42]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[43]  Hsuan-Cheng Huang,et al.  Functional Analysis and Characterization of Differential Coexpression Networks , 2015, Scientific Reports.

[44]  Radu Dobrin,et al.  Pparγ2 Is a Key Driver of Longevity in the Mouse , 2009, PLoS Genetics.

[45]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[46]  Benjamin S. Glicksberg,et al.  Identification of type 2 diabetes subgroups through topological analysis of patient similarity , 2015, Science Translational Medicine.

[47]  Ivan Molineris,et al.  Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs) , 2013, BMC Bioinformatics.

[48]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[49]  H. Stefánsson,et al.  Genetics of gene expression and its effect on disease , 2008, Nature.

[50]  David A. Gough,et al.  Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors , 2005, J. Chem. Inf. Model..

[51]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[52]  Ryen W. White,et al.  Web-scale pharmacovigilance: listening to signals from the crowd , 2013, J. Am. Medical Informatics Assoc..

[53]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[54]  Vijay S. Pande,et al.  Massively Multitask Networks for Drug Discovery , 2015, ArXiv.

[55]  A Ziegler,et al.  Data Analysis and Data Mining: Current Issues in Biomedical Informatics , 2011, Methods of Information in Medicine.

[56]  Robert F. Murphy,et al.  Efficient discovery of responses of proteins to compounds using active learning , 2013, BMC Bioinformatics.

[57]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[58]  Jimeng Sun,et al.  Limestone: High-throughput candidate phenotype generation via tensor factorization , 2014, J. Biomed. Informatics.

[59]  Evan Bolton,et al.  An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..

[60]  David F. Horrobin,et al.  Realism in drug discovery—could Cassandra be right? , 2001, Nature Biotechnology.

[61]  Katarzyna H. Kaminska,et al.  Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding , 2013, Molecular systems biology.

[62]  Armando Blanco,et al.  ProphNet: A generic prioritization method through propagation of information , 2014, BMC Bioinformatics.

[63]  D C Swinney,et al.  Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.

[64]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[65]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[66]  Samuel Kaski,et al.  Probabilistic drug connectivity mapping , 2014, BMC Bioinformatics.

[67]  A. Butte,et al.  Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds , 2015, CPT: pharmacometrics & systems pharmacology.

[68]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[69]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[70]  L. Ferry,et al.  EFFICACY AND SAFETY OF BUPROPION SR FOR SMOKING CESSATION: DATA FROM CLINICAL TRIALS AND FIVE YEARS OF POSTMARKETING EXPERIENCE , 2003, International journal of clinical practice.

[71]  Matthias E. Futschik,et al.  Targeting molecular networks for drug research , 2014, Front. Genet..

[72]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[73]  S. Haggarty,et al.  Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation , 2010, Science.

[74]  Chao Sima,et al.  Inference of Gene Regulatory Networks Using Time-Series Data: A Survey , 2009, Current genomics.

[75]  Hsiang-Yuan Yeh,et al.  Inferring drug-disease associations from integration of chemical, genomic and phenotype data using network propagation , 2013, BMC Medical Genomics.

[76]  B. Zupan,et al.  Discovering disease-disease associations by fusing systems-level molecular data , 2013, Scientific Reports.

[77]  Wei-liang Zhu,et al.  Pharmacophore-based virtual screening versus docking-based virtual screening: a benchmark comparison against eight targets , 2009, Acta Pharmacologica Sinica.

[78]  Christopher A. Lipinski,et al.  Phenotypic In Vivo Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates , 2012 .

[79]  Lixia Yao,et al.  Electronic health records: Implications for drug discovery. , 2011, Drug discovery today.

[80]  J. Arrowsmith,et al.  Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.

[81]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[82]  Yoshihiro Yamanishi,et al.  Supervised prediction of drug–target interactions using bipartite local models , 2009, Bioinform..

[83]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[84]  Kiyoko F. Aoki-Kinoshita,et al.  From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..

[85]  Philip E. Bourne,et al.  Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..

[86]  Chang Liu,et al.  Predicting Drug–Target Interactions Using Probabilistic Matrix Factorization , 2013, J. Chem. Inf. Model..

[87]  M. Welsh,et al.  A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function. , 2014, American journal of respiratory cell and molecular biology.

[88]  Weida Tong,et al.  Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis , 2014, Genome Medicine.

[89]  Cheng Zhu,et al.  Drug repositioning for orphan diseases , 2011, Briefings Bioinform..

[90]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[91]  Hongyi Zhou,et al.  FINDSITEcomb: A Threading/Structure-Based, Proteomic-Scale Virtual Ligand Screening Approach , 2013, J. Chem. Inf. Model..

[92]  C E Lipscomb,et al.  Medical Subject Headings (MeSH). , 2000, Bulletin of the Medical Library Association.

[93]  Tyler Weirick,et al.  LacSubPred: predicting subtypes of Laccases, an important lignin metabolism-related enzyme class, using in silico approaches , 2014, BMC Bioinformatics.

[94]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[95]  Yanli Wang,et al.  Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.

[96]  Aviv Bergman,et al.  Cancer as the Disintegration of Robustness: Population-Level Variance in Gene Expression Identifies Key Differences Between Tobacco- and HPV-Associated Oropharyngeal Carcinogenesis. , 2015, Archives of pathology & laboratory medicine.

[97]  Dong-Sheng Cao,et al.  Genome-Scale Screening of Drug-Target Associations Relevant to Ki Using a Chemogenomics Approach , 2013, PloS one.

[98]  Ivan D. Rukhlenko,et al.  Quantum-dot supercrystals for future nanophotonics , 2013, Scientific Reports.

[99]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[100]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[101]  Brian K. Shoichet,et al.  Virtual Screening in Drug Discovery , 2005 .

[102]  M. Milik,et al.  Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.

[103]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[104]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[105]  Hui Liu,et al.  Improving compound–protein interaction prediction by building up highly credible negative samples , 2015, Bioinform..

[106]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[107]  Nci Dream Community A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[108]  Shu-Dong Zhang,et al.  Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping , 2011, PloS one.

[109]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[110]  Rong Li,et al.  Inductive matrix completion for predicting adverse drug reactions (ADRs) integrating drug–target interactions , 2015 .

[111]  G. Tseng,et al.  Beyond modules and hubs: the potential of gene coexpression networks for investigating molecular mechanisms of complex brain disorders , 2014, Genes, brain, and behavior.

[112]  U. Koch,et al.  Cheminformatics at the interface of medicinal chemistry and proteomics. , 2014, Biochimica et biophysica acta.

[113]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[114]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[115]  K. Andrews,et al.  Drug repurposing and human parasitic protozoan diseases , 2014, International journal for parasitology. Drugs and drug resistance.

[116]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[117]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[118]  Jürgen Bajorath,et al.  Design and Evaluation of a Molecular Fingerprint Involving the Transformation of Property Descriptor Values into a Binary Classification Scheme , 2003, J. Chem. Inf. Comput. Sci..

[119]  Gang Feng,et al.  Disease Ontology: a backbone for disease semantic integration , 2011, Nucleic Acids Res..

[120]  J. Skolnick,et al.  Comprehensive prediction of drug-protein interactions and side effects for the human proteome , 2015, Scientific Reports.

[121]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[122]  Wei Zheng,et al.  Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.

[123]  Pankaj Agarwal,et al.  Systematic evaluation of connectivity map for disease indications , 2014, Genome Medicine.

[124]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[125]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[126]  Armando Blanco,et al.  DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data , 2015, Artif. Intell. Medicine.

[127]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.

[128]  Hao Ye,et al.  Construction of Drug Network Based on Side Effects and Its Application for Drug Repositioning , 2014, PloS one.

[129]  Wei Ma,et al.  RxNorm: prescription for electronic drug information exchange , 2005, IT Professional.

[130]  Atul J. Butte,et al.  Evaluation and integration of 49 genome-wide experiments and the prediction of previously unknown obesity-related genes , 2007, Bioinform..

[131]  Jun Hu,et al.  Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning , 2014, J. Am. Medical Informatics Assoc..

[132]  Michael Darsow,et al.  ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..

[133]  Xin Li,et al.  Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach , 2012, BMC Systems Biology.

[134]  G Hripcsak,et al.  Similarity-Based Modeling Applied to Signal Detection in Pharmacovigilance , 2014, CPT: pharmacometrics & systems pharmacology.

[135]  Michelle Dunn,et al.  The National Institutes of Health's Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data , 2014, J. Am. Medical Informatics Assoc..

[136]  Daniel Cressey,et al.  Traditional drug-discovery model ripe for reform , 2011, Nature.

[137]  Rosario M. Piro,et al.  Network medicine: linking disorders , 2012, Human Genetics.

[138]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[139]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[140]  Qiang Shen,et al.  Learning Bayesian networks: approaches and issues , 2011, The Knowledge Engineering Review.

[141]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[142]  Guanghui Hu,et al.  Human Disease-Drug Network Based on Genomic Expression Profiles , 2009, PloS one.

[143]  Jason A. Papin,et al.  Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease , 2012, BMC Systems Biology.

[144]  J. Castle,et al.  An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.

[145]  Sean Ekins,et al.  In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.

[146]  F. Iorio,et al.  Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.

[147]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[148]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.